When Tumor Markers Look Normal but Chemotherapy Is Still Recommended — Why CEA and CA19-9 Don't Measure How Much Cancer Is Left

The first outpatient visit after surgery is often the day when the pathology stage and the treatment plan arrive together, all within a short conversation. Among everything on the paperwork, the tumor marker numbers are usually the first thing a family member can read on their own — and they can feel like a report card. So when the values look low or normal and a six-month chemotherapy schedule is still proposed, two opposite thoughts tend to arrive at once: isn't this good news? and is there something bad in the blood work we haven't been told? This article is a general explanation meant to untangle that confusion.

First, CEA (carcinoembryonic antigen) and CA19-9 are not substances produced only by cancer cells. Normal tissue makes small amounts, and levels can rise with smoking, chronic inflammation, liver or biliary disease, and other conditions unrelated to cancer. The reverse is also common: many people with advanced colorectal cancer have markers that stay within the normal range. CA19-9 in particular barely rises in people who genetically lack the related blood-group antigen (Lewis-negative), even when cancer is present. These numbers are not a ruler for tumor burden; they are reference values that behave very differently from person to person. That is why two patients with the same stage can have wildly different results.

So what actually drives the decision about adjuvant chemotherapy after surgery? The backbone is the pathologic stage determined under the microscope from the removed specimen — how deeply the tumor invaded the bowel wall (T) and how many of the removed lymph nodes contained cancer (N). Additional risk features are layered on top: lymphovascular or perineural invasion, whether the resection margins were clear, how many lymph nodes were examined, and whether there was obstruction or perforation before surgery. Stage III means lymph node involvement was confirmed, and a higher number of involved nodes raises concern that microscopic cancer cells may remain somewhere in the body. Adjuvant chemotherapy targets those invisible cells to lower the chance of recurrence — it is not treatment aimed at a mass that can currently be seen or measured. That is precisely why it can be recommended even when markers are low and scans show nothing.

There is one more practical point about markers around the time of surgery. CEA clears from the bloodstream relatively quickly, so after a tumor is removed the level usually falls within a few weeks. A single value drawn right after surgery therefore says little on its own; what matters more is how the number trends over time against that individual's own baseline. Conversely, someone whose marker was already normal before surgery may not show a rise even if recurrence later develops, which makes keeping to the scheduled CT scans and colonoscopies more important rather than less. A low number does not mean follow-up can be relaxed.

Some questions are worth writing down before the visit: how many of the removed lymph nodes were involved, whether the margins were clear, whether the goal of this chemotherapy is to reduce recurrence risk, how many cycles are planned and whether they can be adjusted, and how often markers and imaging will be checked from now on. Bringing that list is usually far more reassuring than searching a single number online at night. And when a clinician says the blood work "looks good," it generally means the overall condition of the body can support starting treatment.

Finally, feeling anxious before the first cycle is a completely ordinary reaction for both patients and caregivers. Lab values are one ingredient among many; the plan is built from pathology, overall health, and the patient's own wishes together. Saying the worry out loud in the consultation room is often the quickest route to relief.

Note: This article is general health information intended to aid understanding and does not replace individual diagnosis or medical care. Interpretation of test results and treatment decisions differ from person to person, so please discuss your situation with your own medical team.